The UCPMP is voluntary and there is no legal penalty for violating the code
In a Q&A, the firm's US business head and its group CFO talk about their plans to scale the specialty products business further, and dwell on the company's strategies post-pandemic
Excluding the strong US show led by Revlimid, Q2 was a mixed bag
India will not impose anti-dumping duty on a Chinese chemical used in pharma industry as the finance ministry has not accepted the recommendations of DGTR for imposing the levy. The commerce ministry's investigation arm DGTR had conducted a probe into the alleged dumping of "(4R-Cis)-1-1-Dimethylethyl-6-cyanomethyl-2, 2-dimethyl-1, 3-dioxane-4-acetate" from China, and in August it recommended the imposition of the duty. "The central government, after considering the final findings of the designated authority (DGTR), has decided not to accept the ... recommendations," a memorandum of Department of Revenue said. While Directorate General of Trade Remedies (DGTR) recommends the duty, Department of Revenue takes the final decision to impose it. This chemical is also known as ATS-8, which is a key raw material for manufacturing Atorvastatin active pharmaceutical ingredient. In international trade parlance, dumping happens when a country or a firm exports an item at a price lower than
Pharma industry insiders claimed that most contamination-related problems arise due to solvents
Sales declining anyway and there is no need to ban because of alleged misuse, say experts
The industry is divided on the issue of phasing out codeine-based cough syrups, which are used by many as intoxicants
Candle Partners study shows that from the peak of 30% of gross block in FY16, the capex is down to 9-10% of gross block
Medicines to treat diabetes, HIV, TB, contraceptives, hormonal medicines included in National List of Essential Medicines
As Global pharma majors are exiting South America post Covid, the Pharmaceuticals Export Promotion Council of India (Pharmexcil) is looking to promote Indian pharmaceutical exports in the LAC
Brand named Kerendia (finerenone) will cost Rs 97.5 per day as treatment cost in India
The Centre's recent move to impose GST on services rendered by the markets regulator, Securities and Exchange Board of India (Sebi), has rattled FPIs
The industry is now talking about breaking into the top-10 countries in terms of value by 2030, and entering the top-5 club by 2047
Some are managing supply-chain backend for retail pharmacies, right from stockist to chemist, others are offering telemedicine kiosks at chemist outlets, and digitising pharmacies
Hospitals back to normalcy; tough road ahead for diagnostics
Time has come for the Indian pharmaceuticals industry to move from 'volume' to 'value' leadership to capture global market and the government is committed to supporting companies with industry-friendly policies, Union minister Mansukh Mandaviya said on Saturday. Addressing an interactive session with Indian Pharmaceutical Alliance, the Minister for Chemicals & Fertilizers and Health & Family Welfare also asked the homegrown firms to learn from global best practices and develop own models to meet domestic demand while increasing international footprint. "Let us move from 'Volume' to 'Value' leadership to capture global pharmaceutical market," an official statement said, quoting Mandaviya. He further said, "It is time to accumulate knowledge from global best practices in research, manufacturing and innovation and develop our own models focused on accelerating production to meet the domestic demand while increasing our global footprint." The minister also pushed for making the .
Under the terms of the agreement, Dr Reddy's acquired the Eton portfolio for an upfront payment of approximately USD 5 million in cash, besides contingent payments of up to USD 45 million
Mandaviya, who is also the Minister for Health and Family Welfare, said that the Narendra Modi-led government at the Centre is not only pro-poor and pro-farmer but "industry-friendly" as well
Operating performance may remain weak due to regulatory issues, says rating agency.
While the NPPA may allow a 10 per cent rise in prices of NLEM drugs based on WPI this year, the actual price rise could be less, say drug firms